Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 7/20 | 0.57 |
| ▸ | HTR1A | P08908 | 16/20 | 0.55 |
| ▸ | HTR1B | P28222 | 4/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198528 | 1.00 | HTR1D (0.57) | HTR1DHTR1AHTR1BDRD2ADRA1D | |
| Hydrochloric Acid SCHEMBL4184484 | 0.99 | HTR1D (0.56) | HTR1DHTR1AHTR1BDRD2ADRA1D | |
| SCHEMBL13927802 | 0.95 | HTR1A (0.57) | HTR1DHTR1AHTR1BDRD2SLC6A4 | |
| SCHEMBL13927805 | 0.95 | HTR1A (0.57) | HTR1DHTR1AHTR1BDRD2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4198570 | 0.95 | HTR1A (0.56) | HTR1DHTR1AHTR1BDRD2SLC6A4 | |
| Hydrochloric Acid SCHEMBL4191437 | 0.95 | HTR1A (0.56) | HTR1DHTR1AHTR1BDRD2SLC6A4 | |
| SCHEMBL4189183 | 0.91 | HTR1A (0.56) | HTR1DHTR1AHTR1BDRD2SLC6A4 | |
| SCHEMBL4188619 | 0.91 | HTR1A (0.56) | HTR1DHTR1AHTR1BDRD2SLC6A4 | |
| SCHEMBL13927808 | 0.90 | SLC6A4 (0.63) | HTR1DHTR1AHTR1BDRD2ADRA1D | |
| Hydrochloric Acid SCHEMBL4187177 | 0.89 | SLC6A4 (0.62) | HTR1DHTR1AHTR1BDRD2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008150848-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042874-A1 | ANTIDEPRESSANT HETEROARYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | HTR5A, CRH, CYP17A1 | HTR1D 80/4885HTR1A 77/4885HTR1B 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.